Tiziana Life Sciences plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tiziana Life Sciences plc
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
The latest NDA and BLA submission news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Large Molecule
- Other Names / Subsidiaries
- LonGevia Genomics Srl
- Shardna SpA
- Tiziana Group
- Tiziana Life Sciences Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.